Automated blood glucose control in type 1 diabetes: A review of progress and challenges = Control automatizado de la glucosa en la diabetes tipo 1: revisión del progreso y los desafíos
Since the 2000s, research teams worldwide have been working to develop closedloop (CL) systems able to automatically control blood glucose (BG) levels in patients with type 1 diabetes. This emerging technology is known as artificial pancreas (AP), and its first commercial version just arrived in the...
| Autores: | , , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión aceptada para publicación |
| Fecha de publicación: | 2017 |
| País: | España |
| Recursos: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:10256/15011 |
| Acesso em linha: | http://hdl.handle.net/10256/15011 |
| Access Level: | acceso abierto |
| Palavra-chave: | Diabetis -- Tractament Diabetes -- Treatment Pàncrees artificial Artificial Pancreas Control automàtic Automatic control Control intel·ligent Intelligent control systems |
| Resumo: | Since the 2000s, research teams worldwide have been working to develop closedloop (CL) systems able to automatically control blood glucose (BG) levels in patients with type 1 diabetes. This emerging technology is known as artificial pancreas (AP), and its first commercial version just arrived in the market. The main objective of this paper is to present an extensive review of the clinical trials conducted since 2011, which tested various implementations of the AP for different durations under varying conditions. A comprehensive table that contains key information from the selected publications is provided, and the main challenges in AP development and the mitigation strategies used are discussed. The development timelines for different AP systems are also included, highlighting the main evolutions over the clinical trials for each system |
|---|